NCT00137930View on ClinicalTrials.gov

Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

August 31, 2005

Study Completion Date

November 30, 2005

Conditions
Infections, Rotavirus
Interventions
BIOLOGICAL

Live attenuated rotavirus vaccine

Trial Locations (5)

15140

GSK Investigational Site, Lahti

20520

GSK Investigational Site, Turku

28120

GSK Investigational Site, Pori

33200

GSK Investigational Site, Tampere

90100

GSK Investigational Site, Oulu

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00137930 - Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis | Biotech Hunter | Biotech Hunter